Expertise in
16
conditions

Dr. Matthew S. Block

Oncology | Hematology | Hematology Oncology
Rochester, MN 
Accepting New Patients
Expertise in
16
conditions
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Block is an Oncologist and a Hematologist in Rochester, Minnesota. Dr. Block is highly rated in 16 conditions, according to our data. His top areas of expertise are Melanoma, Ovarian Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma. Dr. Block is currently accepting new patients.

His clinical research consists of co-authoring 104 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medica
  • EPO
  • HMO
  • PPO

Locations

MAYO CLINIC
Rochester, MN 55902
Other Locations
MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Additional Areas of Focus

Dr. Block has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Vemurafenib
Study Phase: Phase 2
Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Enrollment Status: Terminated
Publish Date: June 12, 2025
Intervention Type: Procedure, Biological
Study Drugs: Pembrolizumab, Therapeutic Autologous Dendritic Cells
Study Phase: Phase 1/Phase 2
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Biological, Other
Study Drug: Multi-Epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Study Phase: Early Phase 1
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta and Tyrosinase Related Protein 1
Study Phase: Phase 1
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Gemcitabine Hydrochloride, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Ibrutinib, Pembrolizumab
Study Phase: Phase 1
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug, Other, Biological
Study Phase: Phase 1
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma
A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drugs: [203Pb]VMT01, [68Ga]VMT02
Study Phase: Phase 1
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

104 Total Publications

Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database.
Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database.
Journal: Journal of gastrointestinal cancer
Published: April 20, 2025
Similar Doctors
Expertise in
49
conditions
Dr. Ronald S. Go
Hematology | Oncology | Hematology Oncology
Expertise in
49
conditions
Dr. Ronald S. Go
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.8 mi)
507-284-2511
Languages Spoken:
English, Filipino, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Go is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Go is highly rated in 49 conditions, according to our data. His top areas of expertise are Rosai-Dorfman Disease, Erdheim-Chester Disease, Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Go is currently accepting new patients.

Expertise in
39
conditions
Dr. Naseema Gangat
Hematology | Oncology | Hematology Oncology
Expertise in
39
conditions
Dr. Naseema Gangat
Hematology | Oncology | Hematology Oncology

Mayo Clinic

Rochester, MN 
 (0.1 mi)
507-255-5123
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Naseema Gangat is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Gangat is highly rated in 39 conditions, according to our data. Her top areas of expertise are Leukocytosis, Essential Thrombocythemia, Myelofibrosis, Bone Marrow Aspiration, and Splenectomy. Dr. Gangat is currently accepting new patients.

Expertise in
20
conditions
Dr. David M. Dingli
Hematology | Oncology | Hematology Oncology
Expertise in
20
conditions
Dr. David M. Dingli
Hematology | Oncology | Hematology Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.8 mi)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Dingli is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Dingli is highly rated in 20 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant. Dr. Dingli is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Block's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 8 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile